Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis

Fig. 7

YM101 ameliorates radiation-induced pulmonary fibrosis (RIPF). (a) Schematic diagrams for intervention of RILF model. C57BL/6 mice (n = 12) underwent thoracic irradiation (a single dose of 20 Gy), and after 4 months and 6 months, were treated with isotype, anti-TGF-β, anti-PD-L1, or YM101. 6 mice sacrificed 16 months post RT, and 6 mice sacrificed 24 months post RT. (b-c) Representative images of H&E (upper panel) and Masson’s trichrome staining (lower panel) of right lung sections from mice surviving 4- (b) and 6- (c) months post RT. Scale bars represent 100 μm. Blue stain in lower panel indicates collagen deposition. (d) Ashcroft score was used to determine the pulmonary fibrosis degree. (e-f) The hydroxyproline (HYP) content (µg of HYP per mg of wet lung tissue) in left lung homogenates at 4- and 6-months post-RT (n = 6 per group). The data are expressed as mean ± SEM. **P < 0.01, ***P < 0.001; **** P < 0.0001

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us